
    
      The purpose of this treatment trial is to study the effect of systemic erythropoietin in
      patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax
      10000 IU subcutaneous twice daily for three days).

      Follow up after one month and three months by recording visual acuity and electro
      physiological studies.
    
  